Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A method of isolating IgA present in a sample, the method comprising at least the steps of :

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA to form a complex;

Separating the complex; and,

Releasing IgA from the complex.

2. (Original) A method of isolating C5 present in a sample, the method comprising at least the steps of :

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5 to form a complex;

Separating the complex; and,

Releasing C5 from the complex.

3. (Original) A method for isolating IgA from a sample, the method comprising at least the steps of :

Providing a matrix to which a SET1 protein or functional equivalent is bound;

Providing a sample;

Bringing said matrix and said sample into contact for a period sufficient to allow

SET1 or functional equivalent thereof to bind to IgA present in the sample; and,

Releasing IgA from the matrix.

4. (Original) A method as claimed in claim 3 wherein the method further comprises the step of collecting the IgA released.

Applicant : John David Fraser et al.
Serial No. : Not Yet Assigned
Filed : September 25, 2006
Page : 4 of 7

Attorney's Docket No.: 11752-012US1 / SHR
504430USPR

5. (Currently amended) A method as claimed in ~~claims 3 or 4~~ claim 3 wherein the matrix is in the form of a column over which the sample is passed.

6. (Currently amended) A method as claimed in ~~any one of claims 3 to 5~~ claim 3 wherein the method further comprises the step of washing contaminants present in the sample from the matrix prior to release of IgA.

7. (Currently amended) A method as claimed in ~~any one of claims 3 to 6~~ claim 3 wherein the matrix is Sepharose.

8. (Currently amended) A method as claimed in ~~any one of claims 3 to 7~~ claim 3 wherein the sample is milk.

9. (Currently amended) A method as claimed in ~~any one of claims 3 to 7~~ claim 3 wherein the sample is colostrum.

10. (Currently amended) A method as claimed in ~~any one of claims 3 to 7~~ claim 3 wherein the sample is serum.

11. (Currently amended) A method as claimed in ~~any one of claims 3 to 7~~ claim 3 wherein the method further comprises the step of determining the quantity of IgA present in the sample.

12. (Currently amended) A method as claimed in ~~any one of claims 3 to 11~~ claim 3 wherein IgA is released from the matrix using a 100mM glycine buffer at pH 3.0.

13. (Original) A method for isolating C5 from a sample, the method comprising at least the steps of:

Providing a matrix to which a SET1 protein or functional equivalent is bound;

Providing a sample;

Bringing said matrix and said sample into contact for a period sufficient to allow SET1 or functional equivalent thereof to bind toC5 present in the sample; and,

Releasing C5 from the matrix.

14. (Original) A method as claimed in claim 13 wherein the method further comprises the step of collecting the C5 released.

15. (Currently amended) A method as claimed in claim 13 ~~or 14~~ wherein the matrix is in the form of a column over which the sample is passed.

16. (Currently amended) A method as claimed in ~~any one of claims 13 to 15~~ claim 13 wherein the method further comprises the step of washing contaminants present in the sample from the matrix prior to release of C5.

Applicant : John David Fraser et al.
Serial No. : Not Yet Assigned
Filed : September 25, 2006
Page : 5 of 7

Attorney's Docket No.: 11752-012US1 / SHR
504430USPR

17. (Currently amended) A method as claimed in ~~any one of claims 13 to 16~~ claim 13 wherein the matrix is Sepharose.

18. (Currently amended) A method as claimed in ~~any one of claims 13 to 17~~ claim 13 wherein the sample is milk.

19. (Currently amended) A method as claimed in ~~any one of claims 13 to 17~~ claim 13 wherein the sample is colostrum.

20. (Currently amended) A method as claimed in ~~any one of claims 13 to 17~~ claim 13 wherein the sample is serum.

21. (Currently amended) A method as claimed in ~~any one of claims 13 to 20~~ claim 13 wherein the method further comprises the step of determining the quantity of C5 present in the sample.

22. (Currently amended) A method as claimed in ~~any one of claims 13 to 21~~ claim 13 wherein C5 is released in low pH buffer such as 50mM acetate pH 3.5.

23. (Original) A method of detecting IgA in a sample, the method comprising at least the steps of:

Contacting a sample with SET1 or functional equivalent thereof for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA; and,

Detecting bound SET1 or functional equivalent thereof.

24. (Original) A method of detecting C5 in a sample, the method comprising at least the steps of:

Contacting a sample with SET1 or functional equivalent thereof for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5; and,

Detecting bound SET1 or functional equivalent thereof.

25. (Currently amended) A method as claimed in claim 23 ~~or 24~~ wherein the method further includes the step of determining or quantifying the level of bound SET1.

26. (Original) A method as claimed in claim 23 wherein the method is conducted for the purpose of diagnosing IgA abnormality in a subject.

27. (Original) A method as claimed in claim 24 wherein the method is conducted for the purpose of diagnosing C5 abnormality in a subject.

28. (Currently amended) A method as claimed in ~~any one of claims 23 to 26~~ claim 23 wherein the subject is a mammal.

29. (Original) A method as claimed in claim 28 wherein the mammal is a human.

30. (Original) A method of removing IgA from a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to IgA to form a complex; and,

Separating the complex from the sample.

31. (Original) A method of removing C5 from a sample, the method comprising at least the steps of:

Bringing SET1 or a functional equivalent thereof in contact with the sample for a period sufficient to allow SET1 or functional equivalent thereof to bind to C5 to form a complex; and,

Separating the complex from the sample.

32. (Original) An isolated protein having the amino acid sequence SEQ ID NO: 6 or SEQ ID NO: 7.

33. (Original) An isolated nucleic acid encoding a protein of SEQ ID NO: 6 or SEQ ID NO: 7.

34. (Original) An isolated nucleic acid as claimed in claim 30 wherein the nucleic acid sequence is that represented by SEQ ID NO: 12 or SEQ ID NO: 13.

35. (Original) A kit for the detection, isolation, and/or removal of IgA and/or C5 in a sample, the kit comprising at least SET1 or a functional equivalent thereof.

36. (New) A method as claimed in claim 24 wherein the method further includes the step of determining or quantifying the level of bound SET1.

37. (New) A method as claimed in claim 24 wherein the subject is a mammal.